OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Clinical trials for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) explained in plain language.
Never miss a new study
Get alerted when new OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) trials appear
Sign up with your email to follow new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New heart drug shows promise in major trial for thick heart muscle condition
Disease control CompletedThis study tested a new medication, aficamten, in 282 adults with a heart condition that makes the heart muscle too thick and blocks blood flow. The goal was to see if the drug could improve exercise ability and quality of life compared to a placebo. Participants took the drug or…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated May 17, 2026 11:51 UTC
-
Heart drug mavacamten shows Real-World promise in canada
Disease control CompletedThis study reviewed medical charts of 115 Canadian adults with obstructive hypertrophic cardiomyopathy (oHCM) who started taking mavacamten. Researchers wanted to see how the drug improved symptoms and heart function in routine care. The study found that many patients had better …
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 17, 2026 11:50 UTC
-
Heart drug mavacamten shows promise in thick heart muscle disease
Disease control CompletedThis study looked at 222 adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is too thick and blocks blood flow. Researchers compared those who took the drug mavacamten to those on standard therapy. The main goal was to see if mavacamten could …
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Heart Drug's Real-World performance under the microscope
Disease control CompletedThis study looked at how a drug called mavacamten works for people with obstructive hypertrophic cardiomyopathy (oHCM) in real-world medical practice, not just in a controlled trial. Researchers followed 163 adult patients at a single hospital in the US who were prescribed the dr…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC